ANTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- AN2 Therapeutics reported positive data supporting advancement of oral AN2-502998 into a Phase 2 study for chronic Chagas diseaseJun 4, 2026
- AN2 Therapeutics initiated a Phase 2 investigator-led trial of epetraborole for lung diseaseMar 31, 2026
- AN2 Therapeutics announced plans to move oral epetraborole into a Phase 2 trial for polycythemia veraMar 4, 2026
- AN2 Therapeutics received FDA clearance for 90-patient epetraborole trial in lung diseaseJan 12, 2026
- AN2 Therapeutics announces research collaboration with GSK to advance boron-based LeuRS-inhibitors targeting tuberculosis (TB)Nov 10, 2025